Which has higher valuation and earnings, PASG or ACRV?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A

Is PASG or ACRV more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Acrivon Therapeutics N/A -64.43% -57.08%

Does the media prefer PASG or ACRV?

In the previous week, Passage Bio had 5 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 7 mentions for Passage Bio and 2 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.93 beat Passage Bio's score of 0.45 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PASG or PLRX?

Pliant Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A Pliant Therapeutics N/A N/A -$149.34M -$1.84 N/A

Is PASG or PLRX more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Pliant Therapeutics N/A -58.11% -44.37%

Does the media refer more to PASG or PLRX?

In the previous week, Passage Bio had 5 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for Passage Bio and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.94 beat Passage Bio's score of 0.45 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PASG or XBIT?

Passage Bio currently has a consensus target price of $13.25, suggesting a potential upside of 173.20%. Given Passage Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Passage Bio is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PASG or XBIT?

XBiotech is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is PASG or XBIT more profitable?

XBiotech's return on equity of -26.10% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% XBiotech N/A -26.10% -25.06%

Do analysts prefer CYPH or PASG?

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 173.20%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Which has preferable valuation and earnings, CYPH or PASG?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A Passage Bio N/A N/A -$45.52M -$11.84 N/A

Is CYPH or PASG more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -48.33% -42.21% Passage Bio N/A -150.88% -59.78%

Is PASG or MCRB more profitable?

Seres Therapeutics' return on equity of -130.29% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Seres Therapeutics N/A -130.29% -35.35%

Does the media favor PASG or MCRB?

In the previous week, Seres Therapeutics had 5 more articles in the media than Passage Bio. MarketBeat recorded 12 mentions for Seres Therapeutics and 7 mentions for Passage Bio. Seres Therapeutics' average media sentiment score of 1.03 beat Passage Bio's score of 0.45 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Passage Bio (PASG) Competitors

$4.85 +0.15 (+3.19%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$4.84 0.00 (-0.10%)

As of 06/29/2026 07:38 PM Eastern

Compare

PASG vs. ACRV, PLRX, XBIT, CYPH, and MCRB

Should you buy Passage Bio stock or one of its competitors? MarketBeat compares Passage Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Passage Bio include Acrivon Therapeutics (ACRV), Pliant Therapeutics (PLRX), XBiotech (XBIT), Cypherpunk Technologies (CYPH), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

How does Passage Bio compare to Acrivon Therapeutics?

Passage Bio (NASDAQ:PASG) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Passage Bio has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

Acrivon Therapeutics' return on equity of -64.43% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

In the previous week, Passage Bio had 5 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 7 mentions for Passage Bio and 2 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.93 beat Passage Bio's score of 0.45 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Passage Bio presently has a consensus price target of $13.25, indicating a potential upside of 173.20%. Acrivon Therapeutics has a consensus price target of $11.67, indicating a potential upside of 555.43%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Acrivon Therapeutics beats Passage Bio on 10 of the 13 factors compared between the two stocks.

How does Passage Bio compare to Pliant Therapeutics?

Passage Bio (NASDAQ:PASG) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Pliant Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.84	N/A

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pliant Therapeutics' return on equity of -58.11% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Passage Bio has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

In the previous week, Passage Bio had 5 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for Passage Bio and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.94 beat Passage Bio's score of 0.45 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 173.20%. Pliant Therapeutics has a consensus target price of $3.00, indicating a potential upside of 160.87%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Passage Bio beats Pliant Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Passage Bio compare to XBiotech?

Passage Bio (NASDAQ:PASG) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

In the previous week, Passage Bio had 6 more articles in the media than XBiotech. MarketBeat recorded 7 mentions for Passage Bio and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.87 beat Passage Bio's score of 0.45 indicating that XBiotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Passage Bio	Neutral
XBiotech	Very Positive

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

XBiotech's return on equity of -26.10% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
XBiotech	N/A	-26.10%	-25.06%

XBiotech is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Passage Bio currently has a consensus target price of $13.25, suggesting a potential upside of 173.20%. Given Passage Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Passage Bio is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Passage Bio has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Summary

Passage Bio beats XBiotech on 7 of the 13 factors compared between the two stocks.

How does Passage Bio compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Passage Bio had 6 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 7 mentions for Passage Bio and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Passage Bio's score of 0.45 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
Passage Bio	Neutral

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

Cypherpunk Technologies' return on equity of -48.33% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Passage Bio	N/A	-150.88%	-59.78%

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cypherpunk Technologies has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 173.20%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Summary

Passage Bio beats Cypherpunk Technologies on 8 of the 13 factors compared between the two stocks.

How does Passage Bio compare to Seres Therapeutics?

Passage Bio (NASDAQ:PASG) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 173.20%. Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 118.23%. Given Passage Bio's higher possible upside, research analysts clearly believe Passage Bio is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Seres Therapeutics had 5 more articles in the media than Passage Bio. MarketBeat recorded 12 mentions for Seres Therapeutics and 7 mentions for Passage Bio. Seres Therapeutics' average media sentiment score of 1.03 beat Passage Bio's score of 0.45 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seres Therapeutics has higher revenue and earnings than Passage Bio. Seres Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Seres Therapeutics	$790K	95.45	$5.70M	-$5.17	N/A

Seres Therapeutics' return on equity of -130.29% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Seres Therapeutics	N/A	-130.29%	-35.35%

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Passage Bio has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market.

Summary

Seres Therapeutics beats Passage Bio on 10 of the 13 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PASG vs. The Competition

Export

Metric	Passage Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.08M	$3.62B	$6.85B	$12.20B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-0.41	20.93	26.02	24.36
Price / Sales	N/A	345.52	549.85	102.46
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.82	8.71	10.98	6.49
Net Income	-$45.52M	$23.87M	$3.57B	$336.61M
7 Day Performance	-20.75%	3.59%	2.60%	1.25%
1 Month Performance	-15.94%	1.73%	0.93%	0.24%
1 Year Performance	-39.42%	69.03%	36.40%	30.16%

Passage Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PASG Passage Bio	4.5213 of 5 stars	$4.85 +3.2%	$13.25 +173.2%	-26.8%	$15.08M	N/A	N/A	130	Insider Trade Gap Down
ACRV Acrivon Therapeutics	2.0177 of 5 stars	$1.69 +6.6%	$11.67 +592.4%	+48.3%	$72.12M	N/A	N/A	58	News Coverage
PLRX Pliant Therapeutics	2.6823 of 5 stars	$1.17 +0.4%	$3.00 +157.5%	-8.0%	$71.83M	$1.58M	N/A	90	News Coverage
XBIT XBiotech	0.8231 of 5 stars	$2.33 +0.9%	N/A	-16.8%	$71.04M	N/A	N/A	100
CYPH Cypherpunk Technologies	0.6455 of 5 stars	$0.67 -9.7%	N/A	+142.7%	$70.84M	N/A	N/A	40	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PASG) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Passage Bio (PASG) Competitors

PASG vs. ACRV, PLRX, XBIT, CYPH, and MCRB

How does Passage Bio compare to Acrivon Therapeutics?

Summary

How does Passage Bio compare to Pliant Therapeutics?

Summary

How does Passage Bio compare to XBiotech?

Summary

How does Passage Bio compare to Cypherpunk Technologies?

Summary

How does Passage Bio compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Passage Bio (PASG) Competitors

PASG vs. ACRV, PLRX, XBIT, CYPH, and MCRB

How does Passage Bio compare to Acrivon Therapeutics?

Do institutionals and insiders have more ownership in PASG or ACRV?

Which has higher valuation and earnings, PASG or ACRV?

Which has more risk and volatility, PASG or ACRV?

Is PASG or ACRV more profitable?

Does the media prefer PASG or ACRV?

Do analysts prefer PASG or ACRV?

Summary

How does Passage Bio compare to Pliant Therapeutics?

Which has stronger earnings and valuation, PASG or PLRX?

Do insiders and institutionals believe in PASG or PLRX?

Is PASG or PLRX more profitable?

Which has more risk and volatility, PASG or PLRX?

Does the media refer more to PASG or PLRX?

Do analysts prefer PASG or PLRX?

Summary

How does Passage Bio compare to XBiotech?

Does the media prefer PASG or XBIT?

Do insiders & institutionals hold more shares of PASG or XBIT?

Is PASG or XBIT more profitable?

Which has stronger earnings & valuation, PASG or XBIT?

Do analysts rate PASG or XBIT?

Which has more volatility and risk, PASG or XBIT?

Summary

How does Passage Bio compare to Cypherpunk Technologies?

Does the media favor CYPH or PASG?

Which has preferable valuation and earnings, CYPH or PASG?

Is CYPH or PASG more profitable?

Do institutionals & insiders have more ownership in CYPH or PASG?

Which has more volatility & risk, CYPH or PASG?

Do analysts prefer CYPH or PASG?

Summary

How does Passage Bio compare to Seres Therapeutics?

Do analysts prefer PASG or MCRB?

Does the media favor PASG or MCRB?

Which has higher earnings and valuation, PASG or MCRB?

Is PASG or MCRB more profitable?

Do institutionals & insiders have more ownership in PASG or MCRB?

Which has more volatility and risk, PASG or MCRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools